Doran Stephen, Arif Muhammad, Lam Simon, Bayraktar Abdulahad, Turkez Hasan, Uhlen Mathias, Boren Jan, Mardinoglu Adil
Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London, SE1 9RT, United Kingdom.
Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden.
Brief Bioinform. 2021 Sep 2;22(5). doi: 10.1093/bib/bbab061.
The development and progression of cardiovascular disease (CVD) can mainly be attributed to the narrowing of blood vessels caused by atherosclerosis and thrombosis, which induces organ damage that will result in end-organ dysfunction characterized by events such as myocardial infarction or stroke. It is also essential to consider other contributory factors to CVD, including cardiac remodelling caused by cardiomyopathies and co-morbidities with other diseases such as chronic kidney disease. Besides, there is a growing amount of evidence linking the gut microbiota to CVD through several metabolic pathways. Hence, it is of utmost importance to decipher the underlying molecular mechanisms associated with these disease states to elucidate the development and progression of CVD. A wide array of systems biology approaches incorporating multi-omics data have emerged as an invaluable tool in establishing alterations in specific cell types and identifying modifications in signalling events that promote disease development. Here, we review recent studies that apply multi-omics approaches to further understand the underlying causes of CVD and provide possible treatment strategies by identifying novel drug targets and biomarkers. We also discuss very recent advances in gut microbiota research with an emphasis on how diet and microbial composition can impact the development of CVD. Finally, we present various biological network analyses and other independent studies that have been employed for providing mechanistic explanation and developing treatment strategies for end-stage CVD, namely myocardial infarction and stroke.
心血管疾病(CVD)的发生和发展主要归因于动脉粥样硬化和血栓形成导致的血管狭窄,这会引发器官损伤,进而导致以心肌梗死或中风等事件为特征的终末器官功能障碍。考虑CVD的其他促成因素也很重要,包括心肌病引起的心脏重塑以及与其他疾病(如慢性肾脏病)的共病情况。此外,越来越多的证据表明肠道微生物群通过多种代谢途径与CVD相关。因此,解读与这些疾病状态相关的潜在分子机制以阐明CVD的发生和发展至关重要。一系列整合多组学数据的系统生物学方法已成为确定特定细胞类型变化和识别促进疾病发展的信号事件修饰的宝贵工具。在此,我们综述了近期应用多组学方法以进一步了解CVD潜在病因并通过识别新的药物靶点和生物标志物提供可能治疗策略的研究。我们还讨论了肠道微生物群研究的最新进展,重点是饮食和微生物组成如何影响CVD的发展。最后,我们介绍了各种生物网络分析和其他独立研究,这些研究已被用于为终末期CVD(即心肌梗死和中风)提供机制解释并制定治疗策略。